dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccines - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).the use of dengvaxia should be in accordance with official recommendations.
flumist quadrivalent- influenza vaccine live intranasal spray
medimmune, llc - influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen (unii: fv9fgc9yzw) (influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen - unii:fv9fgc9yzw), influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen (unii: l7z42hp5rz) (influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen - unii:l7z42hp5rz), influenza b virus b/austria/1359417/2021 live (attenuated) antigen (unii: jv6nd6vmy5) (influenza b virus b/austria/1359417/2021 live (attenuated) - influenza a virus a/slovenia/2903/2015 (h1n1) live (attenuated) antigen 10000000 [ffu] in 0.2 ml - flumist® quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine [see description (11)] . flumist quadrivalent is approved for use in persons 2 through 49 years of age. do not administer flumist quadrivalent to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11)] including egg protein, or after a previous dose of any influenza vaccine. do not administer flumist quadrivalent to children and adolescents through 17 years of age who are receiving aspirin therapy or aspirin-containing therapy because of the association of reye’s syndrome with aspirin and wild-type influenza infection [see drug interactions (7.1)] . risk summary flumist quadrivalent is not absorbed systemically following intranasal administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations disease-ass
menveo vaccine powder and solvent for solution for injection 0.5ml vials
glaxosmithkline uk ltd - meningococcal group a oligosaccharide; meningococcal group y oligosaccharide; meningococcal group w135 oligosaccharide; meningococcal group c oligosaccharide - powder and solvent for solution for injection
gardasil syr inj
msd - quadrivalent human peppillomavirus (types 6,11,16,18) vaccine - inj - quadrivalent human peppillomavirus (types 6,11,16,18) vaccine,each dose of 0.5ml contains 20mcg of hpv 6 l1 protein,40mcg of hpv - syr
fluquadri junior inactivated quadrivalent influenza vaccine (split virion), influenza virus haemagglutinin 30mcg, 0.25ml suspens
sanofi-aventis australia pty ltd - influenza virus haemagglutinin -
menveo meningococcal (groups y and w-135) oligosaccharide diphtheria crm197 conjugate vaccine
novartis vaccines and diagnostics s.r.l. - neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen (unii: 3o44u6xyqk) (neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen - unii:3o44u6xyqk) - neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen 10 ug in 0.5 ml
flulaval quadrivalent 2023/2024- influenza virus vaccine suspension
id biomedical corporation of quebec - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (uv, formaldehyde inactivated) (unii: a5pts27urj) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (uv, formaldehyde inactivated) - unii:9ha5c4xl36), influenza a virus a/darwin/9/2021 ivr-228 (h3n2) antigen (uv, formaldehyde inactivated) (unii: p483j7gx6d) (influenza a virus a/darwin/9/2021 ivr-228 (h3n2) hemagglutinin antigen (uv, formaldehyde inactivated) - unii:grn94tp8yv), influenza b virus b/austria/1359417/2021 - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (uv, formaldehyde inactivated) 15 ug in 0.5 ml - flulaval quadrivalent is indicated for active immunization for the prevention of disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. flulaval quadrivalent is approved for use in persons aged 6 months and older. do not administer flulaval quadrivalent to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are insufficient data on flulaval quadrivalent in pregnant women to inform vaccine-associated risks. a developmental toxicity study was performed in female rats administered flulaval quadrivalent prior to mating and during gestation and lactation p
fluzone quadrivalent northern hemisphere (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (formaldehyde inactivate
sanofi pasteur inc. - influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (formaldehyde inactivated) (unii: wd5e5vym2e) (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:erb9sj9vmq), influenza a virus a/darwin/9/2021 san-010 (h3n2) antigen (formaldehyde inactivated) (unii: kja387fhb2) (influenza a virus a/darwin/9/2021 san-010 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:6s4y8a8uey), influenza b virus b/phuket/3073/2013 antigen (formaldehy - influenza a virus a/michigan/45/2015 x-275 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - fluzone® quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluzone quadrivalent is approved for use in persons 6 months of age and older. do not administer fluzone quadrivalent to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11) ], including egg protein, or to a previous dose of any influenza vaccine. pregnancy exposure registry sanofi pasteur inc. is maintaining a prospective pregnancy exposure registry to collect data on pregnancy outcomes following vaccination with fluzone quadrivalent during pregnancy. healthcare providers are encouraged to enroll women who receive fluzone quadrivalent during pregnancy in sanofi pasteur inc.'s vaccination pregnancy registry by calling 1-800-822-2463. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general popul
gardasil hpv 6 l1 protein / hpv 11 l1 protein / hpv 16 l1 protein / hpv 18 l1 protein 20,40,40,20 micrograms/0.5ml sterile liquid syringe
merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 20 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 40 microgram; hpv type 18 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: aluminium; histidine; polysorbate 80; borax; water for injections; sodium chloride - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.
flulaval tetra suspension
id biomedical corporation of quebec - haemagglutinin-strain b (victoria); haemagglutinin-strain b (yamagata); haemagglutinin-strain a (h3n2); haemagglutinin-strain a (h1n1) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - haemagglutinin-strain b (victoria) 15mcg; haemagglutinin-strain b (yamagata) 15mcg; haemagglutinin-strain a (h3n2) 15mcg; haemagglutinin-strain a (h1n1) 15mcg - vaccines